Chi Sheng Pharma & Biotech Co., Ltd

TPEX:4111 Voorraadrapport

Marktkapitalisatie: NT$1.5b

Chi Sheng Pharma & Biotech Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Chi Sheng Pharma & Biotech has been growing earnings at an average annual rate of 13.9%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 2.3% per year. Chi Sheng Pharma & Biotech's return on equity is 6.1%, and it has net margins of 6.8%.

Belangrijke informatie

13.9%

Groei van de winst

13.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie18.5%
Inkomstengroei2.3%
Rendement op eigen vermogen6.1%
Nettomarge6.8%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Apr 06
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Mar 10
A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 01
Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Jan 05
Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Dec 10
Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Opbrengsten en kosten

Hoe Chi Sheng Pharma & Biotech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

TPEX:4111 Opbrengsten, kosten en inkomsten (TWD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 241,0827326620
31 Mar 241,0657326221
31 Dec 231,0616926022
30 Sep 231,09011626523
30 Jun 231,11515126222
31 Mar 231,13016425420
31 Dec 221,14317924920
30 Sep 221,10518622718
30 Jun 221,08515021919
31 Mar 221,05912921919
31 Dec 211,02210821919
30 Sep 211,0035623319
30 Jun 219714123519
31 Mar 219534623119
31 Dec 209795922918
30 Sep 201,0057222819
30 Jun 201,0268022719
31 Mar 201,0478523420
31 Dec 191,0237223221
30 Sep 199985723322
30 Jun 199855723322
31 Mar 199644622922
31 Dec 189674222923
30 Sep 189855222724
30 Jun 181,0166022724
31 Mar 181,0326922223
31 Dec 171,0458221923
30 Sep 171,0349121320
30 Jun 171,0128820919
31 Mar 179958520919
31 Dec 169647320719
30 Sep 169464821025
30 Jun 169364620726
31 Mar 169384220325
31 Dec 159323920326
30 Sep 159084019120
30 Jun 159225018718
31 Mar 159255918419
31 Dec 149437317818
30 Sep 1497910417718
30 Jun 1497410517617
31 Mar 1496010617316
31 Dec 139219617116

Kwaliteitswinsten: 4111 has high quality earnings.

Groeiende winstmarge: 4111's current net profit margins (6.8%) are lower than last year (13.6%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: 4111's earnings have grown by 13.9% per year over the past 5 years.

Versnelling van de groei: 4111's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Winst versus industrie: 4111 had negative earnings growth (-51.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.6%).


Rendement op eigen vermogen

Hoge ROE: 4111's Return on Equity (6.1%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden